Abnormal bidirectional plasticity-like effects in Parkinson's disease

Brain

Volumn 134, Issue 8, 2011, Pages 2312-2320

  Huang, Ying Zu ^a   Rothwell, John C ^b   Lu, Chin Song ^a   Chuang, Wen Li ^a   Chen, Rou Shayn ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

depotentiation; dyskinesia; levodopa; long term potentiation; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSKINESIA; ELECTROMYOGRAM; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; LONG TERM POTENTIATION; MALE; MOTOR CORTEX; NERVE CELL PLASTICITY; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPSE; THETA BURST STIMULATION;

EID: 80052009184     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr158     Document Type: Article

References (47)

1. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al. Increased D1 dopamine receptor signaling in levodopa-induced dys-kinesia. Ann Neurol 2005; 57: 17-26. (Pubitemid 40053311)
2. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 13: 798-802. (Pubitemid 28429978)
3. Cenci MA. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S263-7. (Pubitemid 351215253)
4. Centonze D, Costa C, Rossi S, Prosperetti C, Pisani A, Usiello A, et al. Chronic cocaine prevents depotentiation at corticostriatal synapses. Biol Psychiatry 2006; 60: 436-43. (Pubitemid 44292156)
5. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47 (4 Suppl 1): S122-9; discussion S9-30.
6. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 2000; 247 (Suppl 2): II36-42.
7. Cohen J. Statistical power analysis for the behavioral sciences. 2 edn. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
8. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16: 515-20. (Pubitemid 36041158)
9. Eggers C, Fink GR, Nowak DA. Theta burst stimulation over the primary motor cortex does not induce cortical plasticity in Parkinson's disease. J Neurol 2010; 257: 1669-74.
10. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-89; quiz 523. (Pubitemid 47280623)
11. Gentner R, Wankerl K, Reinsberger C, Zeller D, Classen J. Depression of human corticospinal excitability induced by magnetic theta-burst stimulation: evidence of rapid polarity-reversing metaplasticity. Cerebral Cortex 2008; 18: 2046-53.
12. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-32. (Pubitemid 120031867)
13. Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron 2005; 45: 201-6. (Pubitemid 40128115)
14. Huang YZ, Chen RS, Rothwell JC, Wen HY. The after-effect of human theta burst stimulation is NMDA receptor dependent. Clin Neurophysiol 2007; 118: 1028-32. (Pubitemid 46518301)
15. Huang YZ, Rothwell JC, Edwards MJ, Chen RS. Effect of physiological activity on an NMDA-dependent form of cortical plasticity in human. Cerebral Cortex 2008; 18: 563-70. (Pubitemid 351264226)
16. Huang YZ, Sommer M, Thickbroom GW, Hamada M, Pascual-Leonne A, Paulus W, et al. Consensus: new methodologies for brain stimulation. Brain Stimul 2009; 2: 2-13.
17. Huang YZ. The modulation of cortical motor circuits and spinal reflexes using theta burst stimulation in healthy and dystonic subjects. Restor Neurol Neurosci 2010; 28: 449-57.
18. Huang YZ, Rothwell JC, Lu CS, Chuang WL, Lin WY, Chen RS. Reversal of plasticity-like effects in the human motor cortex. J Physiol 2010; 588: 3683-93.
19. Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 2006; 111: 715-28. (Pubitemid 44118432)
20. Iezzi E, Conte A, Suppa A, Agostino R, Dinapoli L, Scontrini A, et al. Phasic voluntary movements reverse the aftereffects of subsequent theta-burst stimulation in humans. J Neurophysiol 2008; 100: 2070-6.
21. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-77.
22. Jhih-Hung Fang J-JJC, Ing-Shiou Hwang, Ying-Zu Huang. Repetitive transcranial magnetic stimulation over the human primary motor cortex for modulating motor control and motor learning. J Med Biol Eng 2010; 30: 193-201.
23. Koch G, Brusa L, Caltagirone C, Peppe A, Oliveri M, Stanzione P, et al. rTMS of supplementary motor area modulates therapy-induced dys-kinesias in Parkinson disease. Neurology 2005; 65: 623-5. (Pubitemid 41170730)
24. Koch G, Brusa L, Carrillo F, Lo Gerfo E, Torriero S, Oliveri M, et al. Cerebellar magnetic stimulation decreases levodopa-induced dyskin-esias in Parkinson disease. Neurology 2009; 73: 113-9.
25. Krakauer JW, Shadmehr R. Consolidation of motor memory. Trends Neurosci 2006; 29: 58-64. (Pubitemid 43063131)
26. Kulla A, Manahan-Vaughan D. Depotentiation in the dentate gyrus of freely moving rats is modulated by D1/D5 dopamine receptors. Cereb Cortex 2000; 10: 614-20. (Pubitemid 30387840)
27. Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 2000; 405: 955-9. (Pubitemid 30435052)
28. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004; 19: 22-8. (Pubitemid 38559616)
29. Molina-Luna K, Pekanovic A, Rohrich S, Hertler B, Schubring-Giese M, Rioult-Pedotti MS, et al. Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS One 2009; 4: e7082.
30. Monte-Silva K, Kuo MF, Thirugnanasambandam N, Liebetanz D, Paulus W, Nitsche MA. Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. J Neurosci 2009; 29: 6124-31.
31. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006; 129 (Pt 4): 1059-69.
32. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bedard PJ, et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 2006; 21: 9-17. (Pubitemid 43273744)
33. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004; 188: 471-9. (Pubitemid 38891607)
34. Otmakhova NA, Lisman JE. D1/D5 dopamine receptors inhibit depoten-tiation at CA1 synapses via cAMP-dependent mechanism. J Neurosci 1998; 18: 1270-9. (Pubitemid 28082413)
35. Ouattara B, Hoyer D, Gregoire L, Morissette M, Gasparini F, Gomez-Mancilla B, et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010; 167: 1160-7.
36. Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005; 12: 956-63. (Pubitemid 41820050)
37. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-6. (Pubitemid 36514698)
38. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008; 29: 327-35.
39. Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain 2009; 132 (Pt 2): 309-18.
40. Robertson EM, Pascual-Leone A, Press DZ. Awareness modifies the skill-learning benefits of sleep. Curr Biol 2004; 14: 208-12. (Pubitemid 38215347)
41. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007; 27: 6995-7005. (Pubitemid 47015907)
42. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 2008; 275: 1392-9. (Pubitemid 351388785)
43. Suppa A, Marsili L, Belvisi D, Conte A, Iezzi E, Modugno N, et al. Lack of long-term potentiation-like plasticity in primary motor cortex in Parkinson's disease. Exp Neurol 2011; 227: 296-301.
44. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 2004; 14: 311-7. (Pubitemid 38759861)
45. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004; 5: 173-83. (Pubitemid 38252474)
46. Walker MP, Brakefield T, Hobson JA, Stickgold R. Dissociable stages of human memory consolidation and reconsolidation. Nature 2003; 425: 616-20. (Pubitemid 37280144)
47. Xu TX, Yao WD. D1 and D2 dopamine receptors in separate circuits cooperate to drive associative long-term potentiation in the prefrontal cortex. Proc Natl Acad Sci USA 2010; 107: 16366-71.